Literature DB >> 26050251

A retrospective study of cutaneous drug reactions in an outpatient population.

Francesco Drago1, Ludovica Cogorno1, Arianna Fay Agnoletti2, Giulia Ciccarese1, Aurora Parodi1.   

Abstract

BACKGROUND: Adverse cutaneous drug reactions (ACDR) are unexpected cutaneous changes occurring at drug dosages that are normally used for disease prophylaxis, diagnosis or treatment.
OBJECTIVE: The aim of the study was to determine the clinical types of ACDR, the causative agents, the latency time between drug intake and onset of ACDR and the recovery time in an outpatient population.
METHOD: Ninety-five patients diagnosed with ACDR at the Department of Dermatology of the University of Genoa between 2003 and 2012 were retrospectively studied.
RESULTS: Antimicrobials, especially cephalosporins, were the most responsible for ACDR, followed by non-steroidal anti-inflammatory drugs and antihypertensives. The most common clinical manifestations were exanthema (42.1%), erythema multiforme (10.53%) and vasculitis (9.53%). Patients with peripheral eosinophilia showed a more severe clinical manifestation, they were treated with systemic therapies and their recovery time was longer.
CONCLUSION: It is important to have an appropriate clinical approach according to the ACDR severity degree. We think that eosinophilia may characterise severe cutaneous eruptions and that it should always be investigated when ACDR is suspected in order to manage the patient with the appropriate treatment.

Entities:  

Keywords:  Adverse effects; Drug reactions; Periperal eosinophilia; Therapy

Mesh:

Substances:

Year:  2015        PMID: 26050251     DOI: 10.1007/s11096-015-0134-z

Source DB:  PubMed          Journal:  Int J Clin Pharm


  8 in total

1.  Adverse drug reactions: definitions, diagnosis, and management.

Authors:  I R Edwards; J K Aronson
Journal:  Lancet       Date:  2000-10-07       Impact factor: 79.321

2.  Drug eruptions: a study including all inpatients and outpatients at a dermatology clinic of a university hospital.

Authors:  R Apaydin; N Bilen; S Dökmeci; D Bayramgürler; G Yildirim
Journal:  J Eur Acad Dermatol Venereol       Date:  2000-11       Impact factor: 6.166

Review 3.  Cutaneous drug reactions.

Authors:  C K Svensson; E W Cowen; A A Gaspari
Journal:  Pharmacol Rev       Date:  2001-09       Impact factor: 25.468

4.  SCORTEN: a severity-of-illness score for toxic epidermal necrolysis.

Authors:  S Bastuji-Garin; N Fouchard; M Bertocchi; J C Roujeau; J Revuz; P Wolkenstein
Journal:  J Invest Dermatol       Date:  2000-08       Impact factor: 8.551

Review 5.  Dermatologic drug reactions.

Authors:  Jeffrey K McKenna; Kristin M Leiferman
Journal:  Immunol Allergy Clin North Am       Date:  2004-08       Impact factor: 3.479

Review 6.  Epidemiology and risk factors for drug allergy.

Authors:  Bernard Y-H Thong; Teck-Choon Tan
Journal:  Br J Clin Pharmacol       Date:  2011-05       Impact factor: 4.335

7.  Severe adverse cutaneous drug eruptions: epidemiological and clinical features.

Authors:  Inès Zaraa; Meriem Jones; Sondes Trojjet; Rym Cheikh Rouhou; Dalenda El Euch; Mourad Mokni; Amel Ben Osman
Journal:  Int J Dermatol       Date:  2011-07       Impact factor: 2.736

8.  Drug Eruptions: An 8-year Study Including 106 Inpatients at a Dermatology Clinic in Turkey.

Authors:  Fatma Akpinar; Emine Dervis
Journal:  Indian J Dermatol       Date:  2012-05       Impact factor: 1.494

  8 in total
  5 in total

Review 1.  Cutaneous Adverse Effects of Neurologic Medications.

Authors:  Eman Bahrani; Chloe E Nunneley; Sylvia Hsu; Joseph S Kass
Journal:  CNS Drugs       Date:  2016-03       Impact factor: 6.497

2.  Clinical Profile and Comparison of Causality Assessment Tools in Cutaneous Adverse Drug Reactions.

Authors:  Ranjana Beniwal; Lalit Kumar Gupta; Ashok Kumar Khare; Asit Mittal; Sharad Mehta; Manisha Balai
Journal:  Indian Dermatol Online J       Date:  2019 Jan-Feb

3.  Comment on 'Negative SARS-CoV-2 antibodies in patients with positive immunohistochemistry for spike protein in pityriasis rosea-like eruptions'.

Authors:  Giulia Ciccarese; Francesco Broccolo; Aurora Parodi; Francesco Drago
Journal:  J Eur Acad Dermatol Venereol       Date:  2022-08-16       Impact factor: 9.228

4.  Dermoscopic Aspects of Cutaneous Adverse Drug Reactions.

Authors:  Gabriela Rossi; André da Silva Cartell; Renato Marchiori Bakos
Journal:  Dermatol Pract Concept       Date:  2021-01-29

5.  Pityriasis rosea and pityriasis rosea-like eruptions: How to distinguish them?

Authors:  Francesco Drago; Giulia Ciccarese; Aurora Parodi
Journal:  JAAD Case Rep       Date:  2018-09-14
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.